Erasca share price logo

Erasca

NASDAQ: ERAS

Mid Cap

$16.19

-0.07

(-0.43%)

as on

Erasca Stock Performance

as on September 5, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $15.77
    $16.40
    downward going graph

    2.59%

    Downside

    1.30%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.41
    $24.28
    downward going graph

    91.32%

    Downside

    49.97%

    Upside

    downward going graph

Erasca share price movements today

Previous Close
$16.26
Open
$16.04
Volume
1.4M
Market Cap
$5.7B
Day's Low - High
$15.77 - $16.40
52 Week Low - High
$1.41 - $24.28

Erasca Historical Returns

1 Month Return
-11.53 %
3 Month Return
+ 22.53 %
1 Year Return
+ 998.65 %
3 Year Return
+ 527.8 %
5 Year Return
-31.82 %

Erasca Stock Fundamentals & Key Indicators

Check Erasca market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.7B

EPS (TTM)

-0.9688

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-147.7M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-78.25%

Erasca vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Erasca with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$5.7B-31.82%NA0.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Erasca Stock including INR - Dollar returns

The Erasca stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Erasca investment value today

Current value as on today

₹11,72,111

Returns

₹10,72,111

(+1.07K%)

Returns from Erasca Stock

₹9,93,919 (+993.92%)

Dollar Impact

₹78,192 (+78.19%)

Analyst Recommendation on Erasca Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Erasca. Average target price of $24.3

Erasca Share Price Target

Get share price movements and forecasts by analysts on Erasca.

What analysts predicted

33.37%UPSIDE

Target Price

$24.3

Current Price

$16.19

Analyzed by

8 Analysts

Target

$24.30

Erasca target price $24.3, a slight upside of 33.37% compared to current price of $16.19. According to 8 analysts rating.

Indian Investors' Interest in Erasca Stock

Search interest for Erasca Stock has increased by 3% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:3% versus previous 30 day period

Erasca Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
-
-
-
4
-
-
-
-
-
Gross Profit
0
-1
0
0
0
0
-
0
0
Operating Income
-38
-67
-37
-35
-35
-38
-34
-32
-37
EBITDA
-34
-44
-30
-31
-30
-29
-29
-28
-182
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
1
0
0
0
0
0
0
0
Income Before Tax
-35
-63
-31
-32
-30
-33
-30
-29
-183
Income Tax Expense
0
-
-
0
-
-
-
-
-
Net Income
-35
-63
-31
-32
-30
-33
-30
-29
-183
Net Profit Margin
0.00%
0.00%
0.00%
-768.16%
0.00%
0.00%
0.00%
0.00%
0.00%

Erasca Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
Gross Profit
0
0
0
-2
-3
-3
-3
Operating Income
-13
-109
-124
-247
-141
-179
-131
EBITDA
-12
-36
-121
-240
-121
-153
-121
Interest Expense
-
0
55
201
-
-
-
Depreciation
0
0
0
2
3
3
3
Income Before Tax
-12
-101
-122
-242
-125
-161
-124
Income Tax Expense
-1
71
27
-4
-
-
-
Net Income
-12
-101
-122
-242
-125
-161
-124
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Erasca Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-63
-31
-32
-30
-33
-30
-29
-183
-44
Operating Cash Flow
-29
-22
-24
-31
-20
-21
-21
-27
-27
Investing Cash Flow
-86
-102
22
34
15
25
24
-243
19
Financing Cash Flow
211
21
0
0
0
0
0
244
3
Change in Cash
96
-103
-1
2
-4
4
3
-26
-4

Erasca Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-101
-122
-242
-125
-161
-124
Operating Cash Flow
-32
-79
-103
-101
-109
-95
Investing Cash Flow
-71
-64
-71
-91
-156
100
Financing Cash Flow
139
439
98
1
240
1
Change in Cash
36
295
-76
-191
-25
6

Mutual Funds that own Erasca Stock

Check out the Mutual Funds with significant holdings in Erasca.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.135832%
10967952
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
1.98838%
6954600
Fidelity Salem Street Trust
0.775017%
2710718
T. ROWE PRICE SMALL-CAP STOCK FUND, INC.
0.728312%
2547359
Fidelity Concord Street Trust
0.68765%
2405141

Global Institutional Holdings in Erasca

Funds
Holdings
Vanguard
4.33%
iShares
3.15%
SPDR
2.49%
Michael Rockefeller
0.81%
Schwab
0.41%

Erasca News & Key Events

  • img

    Today's Timeline - 28 April

    Tue, 10:08 PM

    -

    Erasca shares fell nearly 50% after disclosing a patient death in an early-stage trial of its ERAS-0015 cancer drug.

Insights on Erasca

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ERAS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ERAS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, ERAS stock has moved up by 905.6%

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
OrganisationErasca
Headquarters3115 Merryfield Row, San Diego, CA, United States, 92121
IndustryBiotechnology
CEODr. Jonathan E. Lim M.D.
E-voting on sharesClick here to vote

Key Management of Erasca

Name

Title

Dr. Robert Shoemaker Ph.D.

Chief Scientific Officer

Dr. Lisa Tesvich-Bonora Ph.D.

Chief People Officer

Mr. Brian L. Baker CPA, M.S.

Senior Vice President of Finance

Dr. Jonathan E. Lim M.D.

Co-Founder, Chairman & CEO

Dr. David M. Chacko M.D.

CFO & Chief Business Officer

Dr. Michael D. Varney Ph.D.

Chairman of Research & Development, Scientific Advisory Board Member and Director

Dr. Shannon R. Morris M.D., Ph.D.

Chief Medical Officer

Dr. Nik Chetwyn Ph.D.

Chief Operating Officer

Ms. Alison Tjosvold Milhous

Senior Vice President of Accounting

Mr. Ebun S. Garner Esq., J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Erasca share price today?

Erasca share price today is $16.19 as on at the close of the market. Erasca share today touched a day high of $16.40 and a low of $15.77.

What is the 52 week high and 52 week low for Erasca share?

Erasca share touched a 52 week high of $24.28 on and a 52 week low of $1.41 on . Erasca stock price today i.e. is closed at $16.19,which is 33.32% down from its 52 week high and 1052.31% up from its 52 week low.

What is Erasca's market capitalisation today?

Erasca market capitalisation is $0.01T as on .

How to invest in Erasca Stock (ERAS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Erasca on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Erasca Shares that will get you 0.0926 shares as per Erasca share price of $16.19 per share as on September 5, 2026 at 8:46 am IST.

What is the minimum amount required to buy Erasca Stock (ERAS) from India?

Indian investors can start investing in Erasca (ERAS) shares with as little as ₹94.49 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in Erasca stock (as per the Rupee-Dollar exchange rate as on ). Based on Erasca share’s latest price of $16.19 as on September 5, 2026 at 8:46 am IST, you will get 0.6177 shares of Erasca. Learn more about fractional shares .

What are the returns that Erasca has given to Indian investors in the last 5 years?

Erasca stock has given -31.82% share price returns and 29.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?